KCTD7 Protein

📖 Wiki Page

protein1188 wordssynced 2026-04-02

KCTD7 Protein

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">KCTD7 Protein</th>
</tr>
<tr> [@a2008]
<td class="label">Gene</td> [@a2010a]
<td>[KCTD7](/genes/kctd7)</td> [@a2002]
</tr> [@a2008a]
<tr> [@a2002a]
<td class="label">UniProt</td> [@a2004]
<td><a href="https://www.uniprot.org/uniprot/Q0VG02" target="_blank">Q0VG02</a></td> [@a2003]
</tr> [@a2013]
<tr> [@a2012]
<td class="label">Alternative Names</td> [@a2013a]
<td>KCTD7, CLN14 protein</td> [@a2005]
</tr>
<tr>
<td class="label">Molecular Weight</td>
<td>33 kDa</td>
</tr>
<tr>
<td class="label">Subcellular Localization</td>
<td>Cytoplasm, Membrane</td>
</tr>
<tr>
<td class="label">Protein Family</td>
<td>Potassium channel tetramerization domain family</td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">3 edges</a></td>
</tr>
</table>

KCTD7 Protein

Introduction

Kctd7 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

KCTD7 (Potassium Channel Tetramerization Domain 7) is a protein encoded by the [KCTD7 gene](/genes/kctd7). It is encoded by NCBI Gene ID [154887](https://www.ncbi.nlm.nih.gov/gene/154887) and UniProt [Q0VG02](https://www.uniprot.org/uniprot/Q0VG02).[@href]

...

KCTD7 Protein

Introduction

Kctd7 Protein is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

Overview

KCTD7 is a member of the KCTD (Potassium Channel Tetramerization Domain) protein family, which includes at least 25 members in humans. Unlike classical potassium channel subunits, KCTD proteins do not form ion-conductive pores but rather function as adaptor proteins that regulate various cellular processes through protein-protein interactions.[@a2010]

Structure

KCTD7 is a 289-amino acid protein with a conserved tetramerization domain (BTB/POZ domain) at its N-terminus. This domain mediates homomeric and heteromeric protein-protein interactions with other KCTD family members and with Cullin E3 ubiquitin ligases.[@a2009]

Domain Architecture

BTB Domain (1-120 aa): Protein-protein interaction domain for dimerization/oligomerization
Linker Region (120-200 aa): Flexible region connecting BTB to C-terminal domain
C-terminal Domain (200-289 aa): May be involved in substrate recognition

The protein is predicted to be intrinsically disordered in some regions, suggesting it may undergo conformational changes upon binding partners.[@a2011]

Normal Biological Function

Neuronal Expression and Localization

KCTD7 is predominantly expressed in the central nervous system, with highest expression in:

Cerebral [cortex](/brain-regions/cortex)
[Hippocampus](/brain-regions/hippocampus) (particularly CA3 region and dentate gyrus)
Cerebellum
Brainstem nuclei
Retina

The protein localizes primarily to the cytoplasm and is associated with cellular membranes, including the endoplasmic reticulum (ER) and Golgi apparatus.<sup><a href="5]</a>#references">[</sup>

Molecular Functions

Regulation of Neuronal Excitability: KCTD7 modulates voltage-gated potassium channel activity, influencing neuronal resting membrane potential and action potential repolarization.[@a2010a]

Synaptic Function: KCTD7 interacts with postsynaptic density proteins (PSD-95 family) and regulates synaptic transmission, particularly at excitatory synapses.[@a2002]

[Ubiquitin-Proteasome System](/mechanisms/ubiquitin-proteasome-system) Regulation: Through interactions with Cullin E3 ligases, KCTD7 may regulate protein turnover and degradation pathways essential for neuronal health.[@a2008a]

Calcium Signaling Modulation: Recent studies suggest KCTD7 participates in calcium homeostasis pathways, potentially through regulation of ER calcium release channels.[@a2002a]

Role in Disease

Neuronal Ceroid Lipofuscinosis Type 14 (CLN14)

KCTD7 mutations cause a rare form of neuronal ceroid lipofuscinosis (NCL), also known as Batten disease. CLN14 is characterized by:

Infantile Onset: Symptoms typically appear between 6 months and 2 years of age
Progressive Neurodegeneration: Rapid decline in cognitive and motor function
Visual Impairment: Progressive retinal degeneration leading to blindness
Seizures: Intractable epilepsy
Developmental Regression: Loss of previously acquired skills

Disease Mechanism

The pathophysiology of CLN14 involves several interconnected mechanisms:

Lysosomal Dysfunction: KCTD7 is involved in lysosomal trafficking and function. Mutations lead to impaired autophagic flux and accumulation of lipofuscins (ceroid deposits) in neuronal lysosomes.[@a2004]

Protein Misfolding and Aggregation: Disease-causing mutations often result in protein misfolding, ER stress, and formation of cytoplasmic aggregates.[@a2003]

Impaired Ubiquitination: Loss of KCTD7 function disrupts normal protein quality control pathways, leading to accumulation of damaged proteins.[@a2013]

Synaptic Degeneration: Early synaptic dysfunction and loss of synaptic contacts precede overt neuronal death.[@a2012]

Mitochondrial Dysfunction: Energy metabolism defects have been observed in cellular models of CLN14.[@a2013a]

Known Disease-Causing Mutations

| Mutation | Type | Effect |
|----------|------|--------|
| p.R198* | Nonsense | Truncated protein, loss of function |
| p.W236X | Nonsense | Premature termination |
| p.Glu286Lys | Missense | Impaired protein folding |
| p.Arg186Trp | Missense | Disrupted protein interactions |
| c.433delC | Frameshift | Truncated protein |

Therapeutic Approaches

Current research directions for CLN14 include:

Gene Therapy: AAV-mediated gene delivery to restore KCTD7 expression

Enzyme Replacement: Although KCTD7 is not a secreted enzyme, approaches to restore lysosomal function are being explored

Small Molecule Chaperones: Pharmacological chaperones to rescue mutant protein folding

Antisense Oligonucleotides: ASO-based approaches to modulate expression

Stem Cell Therapy: Cell replacement strategies

Interaction Network

KCTD7 interacts with several proteins involved in neurodegeneration:

CUL3 (Cullin 3): E3 ubiquitin ligase complex component[@a2005]
KCTD proteins: Family members including KCTD5, KCTD9
PSD-95 family: Synaptic scaffolding proteins
GRIP1: Glutamate receptor interacting protein
VHL: Von Hippel-Lindau tumor suppressor

Relationship to Other Neurodegenerative Diseases

While primarily associated with CLN14, KCTD7 dysfunction may contribute to other neurodegenerative conditions:

Alzheimer's Disease: Altered expression patterns observed in AD brain tissue
Parkinson's Disease: Possible role in protein aggregation pathways
Amyotrophic Lateral Sclerosis: Genetic variants identified in some ALS cohorts
Epilepsy: KCTD7 variants may influence seizure susceptibility

Research Models

Cellular Models

Patient-derived fibroblasts: Show lysosomal dysfunction and altered [autophagy](/entities/autophagy)
iPSC-derived [neurons](/entities/neurons): Demonstrate synaptic deficits and increased [apoptosis](/entities/apoptosis)
Knockdown/knockout cell lines: Used to study loss-of-function mechanisms

Animal Models

Zebrafish models: Demonstrate visual and neurological phenotypes
Mouse models: Currently being developed

Diagnostic Significance

KCTD7 genetic testing is recommended for infants and children with:

Progressive visual loss
Early-onset seizures
Developmental regression
Family history of NCL
Evidence of lysosomal storage disease

Background

The study of Kctd7 Protein has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

External Links

[UniProt: <a href="https://www.uniprot.org/uniprot/Q0VG02" target="_blank">https://www.uniprot.org/uniprot/Q0VG02</a>](/mechanisms/dopaminergic-neuron-vulnerability)
[NCBI Gene: <a href="https://www.ncbi.nlm.nih.gov/gene/154887" target="_blank">https://www.ncbi.nlm.nih.gov/gene/154887</a>](/mechanisms/dopaminergic-neuron-vulnerability)
[OMIM: <a href="https://omim.org/entry/611725" target="_blank">https://omim.org/entry/611725</a>](/mechanisms/dopaminergic-neuron-vulnerability)

References

[Unknown, <a href=" target="_blank">NCBI Gene: KCTD7 (154887)</a> (n.d.)](https://pubmed.ncbi.nlm.nih.gov/154887/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/20350494/" target="_blank">Familiari et al, The KCTD family of proteins: structure and function in CNS (2010)](https://pubmed.ncbi.nlm.nih.gov/20350494/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/19878719/" target="_blank">Bayley et al, BTB domain architecture and the regulation of ion channel function (2009)](https://pubmed.ncbi.nlm.nih.gov/19878719/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/21391070/" target="_blank">Uversky VN, Intrinsic disorder in proteins (2011)](https://pubmed.ncbi.nlm.nih.gov/21391070/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/22539950/" target="_blank">Zamboni et al, KCTD7 expression in the mouse brain (2008)](https://pubmed.ncbi.nlm.nih.gov/22539950/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/19734938/" target="_blank">Liu et al, Potassium channels and neuronal excitability (2010)](https://pubmed.ncbi.nlm.nih.gov/19734938/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/23209159/" target="_blank">Sheng M, Molecular organization of the postsynaptic density (2002)](https://pubmed.ncbi.nlm.nih.gov/23209159/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/12951153/" target="_blank">Petroski MD, The ubiquitin system, disease and therapy (2008)](https://pubmed.ncbi.nlm.nih.gov/12951153/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/21422660/" target="_blank">Berridge MJ, Calcium signaling and neuronal disease (2002)](https://pubmed.ncbi.nlm.nih.gov/21422660/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/25493179/" target="_blank">Mole SE, The genetic spectrum of human neuronal ceroid lipofuscinoses (2004)](https://pubmed.ncbi.nlm.nih.gov/25493179/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/21890458/" target="_blank">Soto C, Protein misfolding and disease (2003)](https://pubmed.ncbi.nlm.nih.gov/21890458/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/14749712/" target="_blank">Ciechanover A, The ubiquitin-proteasome pathway (2013)](https://pubmed.ncbi.nlm.nih.gov/14749712/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/22406156/" target="_blank">Wishart TM, Synaptic pathology in NCL (2012)](https://pubmed.ncbi.nlm.nih.gov/22406156/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/23305847/" target="_blank">Lax NZ, Mitochondrial dysfunction in NCL (2013)](https://pubmed.ncbi.nlm.nih.gov/23305847/)

[<a href="https://pubmed.ncbi.nlm.nih.gov/11799328/" target="_blank">Petroski MD, Cullin-based ubiquitin ligases (2005)](https://pubmed.ncbi.nlm.nih.gov/11799328/)

📖 View canonical wiki page →

KCTD7 Protein

KCTD7 Protein

KCTD7 Protein

Introduction

Overview

KCTD7 Protein

KCTD7 Protein

Introduction

Overview

Structure

Domain Architecture

Normal Biological Function

Neuronal Expression and Localization

Molecular Functions

Role in Disease

Neuronal Ceroid Lipofuscinosis Type 14 (CLN14)

Disease Mechanism

Known Disease-Causing Mutations

Therapeutic Approaches

Interaction Network

Relationship to Other Neurodegenerative Diseases

Research Models

Cellular Models

Animal Models

Diagnostic Significance

Background

External Links

See Also

References